Tarsus Pharmaceuticals, Inc. (TARS)
Largest Insider Buys in Sector
TARS Stock Price History Chart
TARS Stock Performance
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops …
Insider Activity of Tarsus Pharmaceuticals, Inc.
Over the last 12 months, insiders at Tarsus Pharmaceuticals, Inc. have bought $0 and sold $2.24M worth of Tarsus Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Tarsus Pharmaceuticals, Inc. have bought $10.86M and sold $15.77M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000 shares for transaction amount of $18,960 was made by Goldberg Andrew D. (director) on 2023‑12‑15.
List of Insider Buy and Sell Transactions, Tarsus Pharmaceuticals, Inc.
| 2024-08-12 | Sale | director | 35,000 0.0914% | $26.08 | $912,961 | +39.18% | ||
| 2024-06-18 | Sale | See Remarks | 10,445 0.0233% | $27.47 | $286,924 | +21.68% | ||
| 2024-03-18 | Sale | Chief Operating Officer | 4,879 0.013% | $30.60 | $149,297 | +11.18% | ||
| 2024-03-18 | Sale | Chief Commercial Officer | 4,766 0.0127% | $30.60 | $145,840 | +11.18% | ||
| 2024-03-18 | Sale | General Counsel | 4,436 0.0118% | $30.60 | $135,742 | +11.18% | ||
| 2024-03-18 | Sale | Chief Human Resources Officer | 4,314 0.0115% | $30.60 | $132,008 | +11.18% | ||
| 2024-03-18 | Sale | President/CEO and Board Chair | 10,415 0.0278% | $30.60 | $318,699 | +11.18% | ||
| 2023-12-27 | Sale | President/CEO and Board Chair | 8,000 0.024% | $20.22 | $161,760 | +61.09% | ||
| 2023-12-20 | Sale | President/CEO and Board Chair | 40,000 0.1223% | $20.27 | $810,623 | +62.35% | ||
| 2023-12-20 | Sale | CHIEF MEDICAL OFFICER | 2,252 0.0068% | $20.00 | $45,040 | +62.35% | ||
| 2023-12-15 | director | 1,000 0.003% | $18.96 | $18,960 | +70.66% | |||
| 2023-11-30 | Sale | General Counsel | 8,356 0.025% | $16.31 | $136,286 | +94.62% | ||
| 2023-11-30 | Sale | Chief Human Resources Officer | 8,355 0.025% | $16.31 | $136,270 | +94.62% | ||
| 2023-11-15 | Sale | President/CEO and Board Chair | 8,000 0.0252% | $18.37 | $146,933 | +75.14% | ||
| 2023-10-18 | Sale | President/CEO and Board Chair | 8,000 0.0245% | $13.24 | $105,920 | +125.00% | ||
| 2023-10-05 | Sale | CHIEF MEDICAL OFFICER | 1,604 0.0051% | $18.00 | $28,872 | +52.54% | ||
| 2023-09-20 | Sale | President/CEO and Board Chair | 8,000 0.0252% | $17.21 | $137,680 | +62.69% | ||
| 2023-08-23 | Sale | President/CEO and Board Chair | 8,000 0.0244% | $17.23 | $137,840 | +48.79% | ||
| 2023-08-15 | director | 9,506 0.035% | $16.80 | $159,701 | +48.59% | |||
| 2023-07-19 | Sale | President/CEO and Board Chair | 103,900 0.3866% | $20.01 | $2.08M | +13.60% |
Insider Historical Profitability
| Vivo Capital IX, LLC | 10 percent owner | 2469001 6.4588% | $54.24 | 1 | 10 | +36.85% |
| Tester Jason E. | 1920933 5.0251% | $54.24 | 1 | 0 | +36.85% | |
| Horowitz Limited Partnership VIII | 10 percent owner | 1920933 5.0251% | $54.24 | 1 | 0 | +36.85% |
| Frazier Life Sciences IX, L.P. | 10 percent owner | 1917157 5.0152% | $54.24 | 1 | 0 | +36.85% |
| Ackermann Michael | 100000 0.2616% | $54.24 | 1 | 9 | +25.23% |
Institutional Investor Ownership
| RTW Investments, LP | $118.95M | 8.66 | 3.27M | +3.81% | +$4.36M | 1.78 | |
| Paradigm BioCapital Advisors LP | $104.08M | 7.58 | 2.86M | +179.36% | +$66.83M | 3.78 | |
| BlackRock | $96.42M | 7.02 | 2.65M | +5.43% | +$4.96M | <0.01 | |
| Morgan Stanley | $87.2M | 6.35 | 2.4M | +22.54% | +$16.04M | 0.01 | |
| Tang Capital Management, LLC | $81.96M | 5.97 | 2.25M | +2.27% | +$1.82M | 0.31 |